Bibliography
- World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus. Available from: http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf [Last accessed 13 August 2008]
- UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
- Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
- The ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
- Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
- Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
- Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in US adults? Diabetes Care 2008;31:81-6
- Chen J, Feder J, Neuhaus I, Whaley JM. Tissue expression profiling of the sodium-glucose co-transporter (SGLT) family: Implication for targeting SGLT2 in type 2 diabetes patients [abstract #2493-PO]. American Diabetes Association, San Francisco, USA, 6 – 10 June 2008
- Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007;106:S27-35
- Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003;89:3-9
- Zelikovic I. Aminoaciduria and glycosuria. Fifth edition. In: Avner ED, Harmon WE, Niaudet P, editors, Pediatric Nephrology. Philadelphia: Lippincott Williams & Wilkins, 2004. p. 701-28
- Moe OW, Wright SH, Palacín M. Renal handling of organic solutes. Eighth edition. In: Brenner BM, editor, Brenner and Rector's The Kidney. Philadelphia: Saunders Elsevier, 2008
- Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+ glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794-800
- Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-9
- Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8
- Scholl-Bürgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant 2004;19:2394-6
- Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-82
- Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-5
- Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-9
- Devenny J, Harvey S, Rooney S, et al. The effect of dapagliflozin (BMS-512148), a selective SGLT2 inhibitor, on body weight in diet-induced obese rats [abstract #384]. North american association for the study of obesity, New Orleans, 22 October 2007
- Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009 [Epub 7 Jan 2009]
- Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009 [Epub 7 Jan 2009]
- List J, Woo V, Morales E, et al. Sodium-glucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care 2008 [Epub 29 Dec 2008]
- Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007;8:285-92
- Oku A, Ueta K, Arakawa K, et al. T-1095, and inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794-800
- Hussey E, Clark R, Amin DM, Kipnes M et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus (Abstract 189-OR). 67th Annual Meeting of the American Diabetes Association, 22 – 26 June, 2007; Chicago, IL, USA
- Harrington WW, Milliken NO, Binz JG, et al. Remogliflozin etabonate, a potent and selective sodium-dependent glucose transporter 2 antagonist, produced sustained metabolic effects in Zucker diabetic fatty rats [abstract #529-P]. American Diabetes Association, San Francisco, 6 – 10 June 2008